

Atty Dkt No: PP00054.009

USSN: 08/453,350

PATENT

AMENDMENT**In the Claims:**

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

25. (Cancelled)

26. (Cancelled)

27. (Previously presented) A recombinant protein preparation comprising a PDGF A-chain homodimer comprised of two disulfide linked chains, each of said chains comprising the amino acid sequence numbered 87-211, inclusive, of Figure 1, or an analog of said sequence that comprises less than 10 amino acid variations and retains PDGF biological activity as measured using a human foreskin fibroblast mitogen assay, wherein said protein preparation is produced in a nonhuman cell such that said protein preparation is free of other human proteins.

28-42. (Cancelled)

43. (Currently amended) The protein preparation of claim ~~25~~ 58, further comprising a pharmaceutically acceptable excipient.

44. (Currently amended) The protein preparation of claim ~~26~~ 59, further comprising a pharmaceutically acceptable excipient.

45. (Previously presented) The protein preparation of claim 27, further comprising a pharmaceutically acceptable excipient.

Atty Dkt No: PP00054.009

USSN: 08/453,350

PATENT

46-54. (Cancelled)

55. (Previously presented) The protein preparation of claim 43, wherein the pharmaceutically acceptable excipient is suitable for topical administration.

56. (Previously presented) The protein preparation of claim 44, wherein the pharmaceutically acceptable excipient is suitable for topical administration.

57. (Currently amended) The protein preparation of ~~claim 44~~ claim 45, wherein the pharmaceutically acceptable excipient is suitable for topical administration.

58. (Currently amended) ~~The A recombinant protein preparation of claim 25, wherein the preparation comprises~~ comprising a PDGF A-chain homodimer comprised of two disulfide linked chains, each of said chains comprising the amino acid sequence numbered 87-193, inclusive, of Figure 1, wherein said protein preparation is produced in a nonhuman cell such that said protein preparation is free of other human proteins.

59. (Currently amended) ~~The A recombinant protein preparation of claim 26, wherein the preparation comprises~~ comprising a PDGF A-chain homodimer comprised of two disulfide linked chains, each of said chains comprising the amino acid sequence numbered 87-196, inclusive, of Figure 1 or the amino acid sequence numbered 87-196, inclusive, of Figure 2, wherein said protein preparation is produced in a nonhuman cell such that said protein preparation is free of other human proteins.

60. (Previously presented) The recombinant protein preparation of claim 27, wherein the preparation comprises a PDGF A-chain homodimer comprised of two disulfide linked chains, each of said chains comprising the amino acid sequence numbered 87-211, inclusive, of Figure 1.

61. (Cancelled)

Atty Dkt No: PP00054.009

USSN: 08/453,350

PATENT

62. (Previously presented) The recombinant protein preparation of claim 27, wherein the analog comprises less than 10 amino acid substitutions.

63. (Cancelled)

64. (Cancelled)

65. (Previously presented) The recombinant protein preparation of claim 62, wherein the analog comprises less than 3 amino acid substitutions.

66. (Cancelled)